Phase II study of age-adjusted R-BAC (Rituximab, Bendamustine, Cytarabine) as induction therapy in older patients with Mantle Cell Lymphoma (MCL)
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Bendamustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms FIL-RBAC500
- 12 Oct 2017 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Final results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 08 Aug 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.